NewLimit is a technology company.
NewLimit has raised $202.0M across 2 funding rounds.
NewLimit has raised $202.0M in total across 2 funding rounds.
NewLimit has raised $202.0M in total across 2 funding rounds.
NewLimit's investors include 8VC, Afore Capital, Andreessen Horowitz, C2 Investment, Caffeinated Capital, Cambrian Ventures, Cubit Capital, General Catalyst, Krishna Yeshwant, NightDragon, Paradigm, Sequoia Capital.
NewLimit is a biotechnology company founded in 2022 that develops epigenetic reprogramming therapies to restore youthful function in aging cells, targeting age-related diseases in the liver, immune, and vascular systems as a path to extending human healthspan.[1][2][3] The company serves patients with unmet needs in aging-related conditions by inventing RNA-based medicines discovered through AI models, single-cell genomics, and functional assays, addressing the functional decline in specific cell types like hepatocytes, T cells, and endothelial cells.[2][3] With 34-43 employees (over 90% in technical roles as of May 2025) and $202.2 million raised across Series A ($40M) and Series B ($130M at $810M valuation), NewLimit demonstrates strong growth momentum, advancing liver mRNA medicines toward clinical trials while scaling research.[1][2]
NewLimit was co-founded in 2022 by Blake Byers, Brian Armstrong (Coinbase co-founder), and Jacob Kimmel, all with deep expertise in biotech, AI, and entrepreneurship, headquartered in South San Francisco, California.[1][2] The idea emerged from advances in epigenetic control of gene expression, aiming to reverse age-related cellular decline by reprogramming old cells to act young via transcription factor combinations delivered as RNA medicines.[2][3] Early traction included an initial funding commitment, followed by a 2023 $40M Series A from Dimension, Founders Fund, Kleiner Perkins, and angels, then a $130M Series B to push programs into clinical development, reflecting rapid validation of their vision.[1][2]
NewLimit rides the convergence of AI, genomics, and longevity biotech, capitalizing on breakthroughs in epigenetic reprogramming to treat aging as a programmable disease rather than inevitable decline.[2][3] Timing is ideal amid surging investor interest in healthspan extension—evidenced by their $810M Series B valuation—and market forces like aging populations, AI-driven drug discovery acceleration, and mRNA tech maturation post-COVID.[1] By pioneering cell-type-specific therapies, NewLimit influences the ecosystem, validating AI-biotech fusion (e.g., for liver and immune rejuvenation) and paving the way for competitors while attracting talent to the field.[1][2][3][4]
NewLimit is poised to advance its lead liver mRNA programs into clinical trials, expand multi-cell-type pipelines, and hire aggressively to hit 20-year healthspan goals, fueled by Series B capital.[1][2] Trends like AI-optimized therapeutics and regulatory shifts toward aging biology will accelerate progress, potentially evolving their influence from niche innovator to longevity category leader. This positions them to redefine medicine, turning cellular aging reversal from sci-fi to standard care—echoing their mission to extend healthy human life.[3]
NewLimit has raised $202.0M across 2 funding rounds. Most recently, it raised $130.0M Series B in May 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2025 | $130.0M Series B | 8VC, Afore Capital, Andreessen Horowitz, C2 Investment, Caffeinated Capital, Cambrian Ventures, Cubit Capital, General Catalyst, Krishna Yeshwant, NightDragon, Paradigm, Sequoia Capital, Thrive Capital, Y Combinator, Arash Ferdowsi, Gokul Rajaram, Julius Genachowski, Matt Macinnis, Thomas Tull | |
| May 1, 2023 | $72.0M Series A | Andreessen Horowitz, Cambrian Ventures, Innovation Endeavors, Luno Expeditions, Paradigm, Timespan Ventures, Tribe Capital, Y Combinator, Alex Adelman, Anshu Sharma, Julius Genachowski |